IAG, Image Analysis Group is comprised of Image Analysis, Ltd. (London, UK), Image Analysis, Inc. (Philadelphia, PA, USA) and Venture Partners. IAG is unique partner to life sciences companies. Our goal is to accelerate novel drug development by using the right analytical tools and modern trial infrastructure.
We bring AI, Machine Learning and smart image analysis methods to ensure the speed and cost-effectiveness, while delivering true insights about your mechanism of action and patients’ response, in real-time.
We leverage our core expertise in medical image analysis, drug development and trial design.
Through quantitative imaging-based assessments, we help our biotech and pharma clients to understand the specifics of their therapeutic agents.
We work with investors and executive teams on deploying the right strategies for early efficacy assessments, objective response prediction and critical analysis of advanced treatment manifestations (such as pseudo-progression in immuno-oncology).
Thus, lowering the investment risks into advanced therapies while helping to accelerate study outcomes.
We have entrepreneurial mindset agile culture and can-do attitude. We are here to create successful partnerships and see more patients cured with the drugs, that we can help you to develop.
OUR HISTORY BY OUR CEO
While studying for her PhD at Leeds, UK Olga Kubassova began work on commercialising her research. She was the first winner of the Sir Peter Thompson Enterprise Award, and ten years on her bright idea has developed into a global business with HQ in London, UK and Philadelphia, USA. In this video, Olga talks about the encouragement she received in establishing the business, the fast growing team and endorsement from blue chip partners, which include top 10 pharmaceutical companies, innovative biotech and medtech players and IAG’s own portfolio companies.
Targeted market assessment, patented benchmarking libraries, analytics platform and the most comprehensive expert advisory board help our clients to formulate clear strategy and design the optimal trial for early go / no go decisions.
Integration of cloud platform, study-specific biomarkers with experience of IAG’ commercial and operational team ensures meeting your business objectives for growth or partnering, fast execution of projects and scientific credibility of the outcomes.
An independent investment division of IAG seeks to partner with biotech companies with promising compounds at early stages of clinical development or academics with IP ready for commercialization.
Innovating together with promising life science companies and securing successful partnering arrangements has yielded spectacular results over the past 10 years. As a trusted partner to many biotech and pharma companies, IAG’s team is proud to share your words.
Since 2007, over 2000 articles were published by IAG’s team and advisory board to cover scientific discoveries, technology break-throughs and special cases. We list here some critically important papers and abstracts.
From the Technology Innovation to the Entrepreneur of the Year, IAG’s team, its founder-CEO and its industry disrupting technology platform DYNAMIKA won 22 awards since 2007. We share, with pride and thanks!
Rigorous quality standards, complience to 21 CFR Part 11, ISO13485, CE, FDA510. Our Quality Management System is certified by British Standards Institute (BSI).
We Are Hiring!
Do you want to join a fast-paced company using computer science, medical imaging and bold thinking to bring the best treatments to patients? We are hiring in Europe and USA giving you an international career, supportive team and ability to make real impact!